Abstract: A formulation for administration to non-human mammals and/or human mammals for the treatment of osteoarthritis includes active ingredients. The active ingredients include (a) an efficacious amount of cannabidiol (“CBD”), a component of a full-spectrum hemp extract (FSHE), or a broad-spectrum hemp extract (BSHE), or a CBD isolate; (b) an efficacious amount of beta-caryophyllene (“BC”); and (c) an efficacious amount caprylic acid (“CA”).

Abstract: Disclosed are devices and methods for improving healing of an enthesis. An effective amount of a composition comprising one or more sex steroids and/or sex steroid equivalents is locally administered at the site of a repaired enthesis. The composition causes upregulation of one or more chondrogenic, angiogenic, and/or tendon modulation genes, resulting in improved healing of the enthesis. The improved enthesis healing occurs even where the subject has normal levels of sex hormones.

Abstract: Derivatives of 10S, 17S-diHIDA (protectin DX, PDX) and medicinal uses thereof are disclosed. These derivatives are specialized pro-resolving mediators (SPRMs). In specific embodiments, said derivatives are used in to prevent or treat viral infections (including influenza and coronavirus infections), insulin resistance, diabetes, and inflammatory disorders.

Abstract: Formulations for treatment of human subjects exposed to, or potentially exposed to SARS-CoV-2 virus, or suffering from COVID-19, comprising a multiple-component antiviral formulation comprising a curcumin component, harmine component, and isovanillin component, and/or variants thereof. The formulation may also be used to inhibit SARS-CoV-2 virus in cell-based assays or in the manufacture of antiviral medicaments.

Abstract: The disclosure is directed to methods of treating depression in a human patient in need thereof, whereby certain patients may be qualified for a reduced monitoring period after a treatment session. The methods are based on an analysis of adverse events and provide treatment options for the patient and healthcare provider.

Abstract: The present invention is to provide a preventive or therapeutic agent for a neurodegenerative disease or a cognitive dysfunction, containing a compound represented by a following formula (I) or a pharmacologically acceptable salt thereof as an active ingredient.

Abstract: This disclosure relates to a method of treating depression and/or reducing risk of suicide, comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan. The combination may be administered twice a day to a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-?sberg Depression Rating Scale (MADRS-SI).

Abstract: There is provided herein compounds of formula I and pharmaceutically acceptable salts thereof, wherein X1, X2, Z, the ring containing Q1 to Q5, m and r have meanings as provided in the description. There is also provided medical uses of such compounds.

Abstract: In general, the invention relates to pharmaceutical compositions comprising (R)-oxybutynin and a norepinephrine reuptake inhibitor (NRI) and methods of treating Sleep Apnea comprising administering (R)-oxybutynin and a norepinephrine reuptake inhibitor (NRI). In some embodiments, the NRI is atomoxetine.

Abstract: The present invention relates to advanced methods of treating a wound comprising the steps of cleansing the wound with an antiseptic formulation, applying an antibiotic formulation to the wound, covering the wound with an adhesive bandage, and repeating these steps for at least two additional, consecutive days.

Abstract: Methods of treating mood disorders with compounds disclosed herein. Also provided are pharmaceutical compositions that include those compounds.

Abstract: The present invention relates to a pharmaceutical combination for use in the treatment, prevention and/or stabilization of age-related diseases and/or degenerative diseases. In particular, said pharmaceutical combination comprises a biguanide and an acetylcholinesterase inhibitor and/or an N-oxide, a hydrate, a pharmaceutically acceptable salt or solvate thereof. The invention is further also directed to the use of said pharmaceutical combination for prevention, stabilization and/or reduction of age-related complaints and/or degenerative complaints; and for improving a measure of life span and/or health span.

Abstract: A method of increasing production of one or more lipoxins in a subject in need thereof comprising administering to the subject an amount of a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, so as to thereby increase production of the one or more lipoxins in the subject.

Abstract: Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.

Abstract: Methods of treating a valvular heart disease are provided. Methods for treating valvular heard disease include administering to a subject a therapeutically effective amount of at least one hedgehog pathway inhibitor. Also provided are methods for reducing fibrosis in a subject, which comprise administering to the subject a therapeutically effective amount of at least one hedgehog pathway inhibitor.

Abstract: There is disclosed a novel monohydrate salt form of denatonium acetate. More particularly, the novel salt form and crystalline hydrate form is useful for the treatment and prevention of diseases and conditions, such as metabolic syndrome, obesity, NASH, glycemic control/diabetes, and IBD (intestinal bowel disease).

Abstract: Methods to interrogate and modulate gut barrier integrity are provided. Methods for treating leaky gut barrier are also provided. Methods for early detection of diseases associated with inflammatory disorders. Methods to rapidly assess the effects of drugs, chemicals, nutritional supplements, vitamins, and probiotics on the integrity of the gut barrier are also provided.

Abstract: An application of potassium ion (K+) channel blocker in preparation of drugs for treating liver fibrosis is provided, which relates to the field of medical technologies. The K+ channel blocker is sotalol, the sotalol is originally used as an antiarrhythmic drug in clinic and has a property of inhibiting K+ channels. Experiments show that sotalol can effectively inhibit liver fibrosis and reduce expression of fibrosis-related protein alpha-smooth muscle actin (?-SMA), specifically by regulating expression and/or function of autophagy and epithelial-mesenchymal transition (EMT) molecules to achieve inhibition of hepatic stellate cell (HSC) fibrosis, so as to provide a new drug choice for clinical treatment of the liver fibrosis.

Abstract: The present invention is directed to antiviral compositions that provide efficacy against non-envelope viruses such as noroviruses. The antiviral compositions comprise an alkyl 2-hydroxycarboxylic acid and an effective amount of a sulfonated surfactant. The composition may be used as a topical on human skin, as a hand sanitizer or as a hard surface cleaning composition.

Abstract: This invention relates to the use of nitroalkene derivatives for the treatment of neurodegenerative conditions in mammals in which neuroinflammation is a contributing factor, such as in amyotrophic lateral sclerosis (ALS).

Abstract: Use of GABA-receptor agonists, either alone or with one or more positive PAMs, anti-inflammatory compounds, and/or antiviral treatments, e.g., one that limits viral replication or impacts other viral functions, to ameliorate, treat, and/or prevent illness arising from infections, including bacterial, fungal, and/or viral infections, in patients, including to: ameliorate infection-related medical conditions; ameliorate and/or prevent coronavirus-related medical conditions; inhibit viral replication; inhibit corona virus replication; ameliorate and/or treat coronavirus-induced medical conditions; ameliorate and/or prevent respiratory virus-related medical conditions; and ameliorate and/or modulate dysregulated immune responses.

Abstract: The present invention relates to amino acid compositions and methods to reduce liver fat and circulating concentration of triacylglycerol. The invention further relates to amino acid compositions for reducing liver fat and circulating triacylglycerol (TG) in individuals with hepatic steatosis (HS). The compositions described herein are pharmaceutical or nutritional compositions. The compositions are based on a specially formulated mixture of essential amino acids (EAAs).

Abstract: The present disclosure describes methods of administering N-acetylcysteine (NAC) via intranasal nose-to-brain administration. The effect of intranasal NAC nose-to-brain administration can be monitored using an analytical technique, for example, magnetic resonance spectroscopy (MRS). In some embodiments, intranasal nose-to-brain NAC can be used to treat a condition, for example, a brain injury.

Abstract: Use of the active compound in the present disclosure for the prevention or treatment of ovarian dysfunction disease. In particular, the present disclosure relates to the use of a compound shown in Formula I or a pharmaceutically acceptable salt thereof in the treatment or prevention of ovarian dysfunction disease, wherein R1 and R2 are each independently selected from H, C1-C6 alkyl, C1-C6 alkenyl, and C1-C6 alkynyl. The present disclosure also relates to the use of a compound shown in said Formula I or a pharmaceutically acceptable salt thereof, in combination with hyodeoxycholic acid or a pharmaceutically acceptable salt thereof, in the treatment or prevention of ovarian dysfunction disease. The present disclosure also relates to compositions comprising a compound shown in said Formula I or a pharmaceutically acceptable salt thereof and/or hyodeoxycholic acid or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to nutritional compositions for maintaining and enhancing one carbon (1C) metabolism. The compositions are useful for maintaining general body health, reducing physiological consequences of metabolic stress, enhancing anabolism in a growing body or in a body recovering from a disease or trauma, activating anabolic processes in the ageing body of a mammal, such as a human individual or domestic animal. The compositions comprise a combination of choline and succinate in the molar ratio 2:1.

Abstract: The present disclosure provides use of doxepin hydrochloride in preparation of an antiviral drug and relates to the technical field of medicine. Studies show that the doxepin hydrochloride exhibits strong antiviral activity against Coxsackievirus B type 1, type 2 and type 3 and has a 50% minimal inhibitory concentration (IC50) value of 10.12±0.85 ?M. In addition, it is also found that the doxepin hydrochloride inhibits virus replication at an early stage of an infection cycle, rather than affecting an entry or assembly process. Meanwhile, some host genes associated with a mechanism are found through target prediction and gene association network analysis. The above findings provide a foundation and a basis for use of the doxepin hydrochloride in treatment of Coxsackievirus B infection.

Abstract: The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof in combination with pimobendan and/or telmisartan or pharmaceutically acceptable forms thereof, in particular for the prophylaxis and/or treatment of one or more cardiac diseases in a non-human mammal/non-human mammal patient, such as a dog or a cat.

Abstract: The present invention relates to a pharmaceutical composition including a CDK inhibitor and an ID2 activator for the prevention or treatment of bladder cancer, wherein based on the finding that: among CDK1-TFCP2L1 pathway targets associated with urothelial differentiation in bladder cancer cells, ID2 is a factor significantly correlating with the tumor grade of bladder cancer; an ID2 activator exhibits a therapeutic effect on bladder cancer; and the combined administration of CDK1 inhibitor and ID2 activator induces apoptosis of bladder cancer cells and significantly suppresses the invasiveness of cancer cells, compared to administration thereof alone, thereby exhibiting a therapeutic effect of remarkably suppressing the size and progression of bladder cancer, a composition comprising a CDK inhibitor and an ID2 activator and a method for combined administration thereof are provided as novel therapeutic means for the prevention or treatment of bladder cancer.

Abstract: The present disclosure administered a cannabinoid medication to a patient followed by observing one or more physiological responses in the patient during a first period of time with treating a medical condition. The cannabinoid medication may include one or more specific types of cannabinoids at a dosage level or may include a plurality of discrete formulations where each formulation includes massed of specific cannabinoids that may be used for treating one or more ailments.

Abstract: Disclosed herein is a method for inhibiting lipogenesis; inhibiting fat accumulation; promoting fat breakdown; reducing body fat; and/or preventing, improving or treating obesity or metabolic diseases. In one aspect, Gallocatechin Gallate (GCG) and Isoquercitrin (IQC) of the present invention have excellent lipid metabolism control effects, can increase mitochondria in adipocytes, and promote the production of brown fat. Therefore, in one aspect, the present invention can provide a method for preventing, improving, or treating obesity or metabolic diseases.

Abstract: The current invention concerns an innovative treatment for mitochondrial disorders and diseases or conditions associated with mitochondrial dysfunction. In particular, effective and safe dosages of compounds suitable for the treatment of mitochondrial disorders have been established, providing for new treatment regimens and patient populations.

Abstract: The invention relates to psychoactive medicines including methylone, 2C-B, MBDB, their respective salts, metabolites, isomers, enantiomers, solvates, isotopologues and isotopomers, polymorphs, prodrugs and analogs (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.

Abstract: Provided are methods of treating various forms of hearing loss caused by aberrant calcium fluxes in auditory cells. The methods encompass the administration of agents which prevent abnormal calcium fluxes, stabilize SERCA2b activity, or prevent ER UPR apoptotic responses. The methods include therapeutic treatments of subjects suffering from hearing loss as well as preventative treatments which protect auditory cells from cell death, for example as caused by exposure to loud noise.

Abstract: A method for treating or preventing a neurodegenerative disease in a subject, the method comprising administering an HGF activating compound in a therapeutically effective amount to treat or prevent the neurodegenerative disease by activating HGF in the subject. The neurodegenerative disease may be, for example, Alzheimer's Disease, Parkinson's Disease, multiple sclerosis, dementia, or mild cognitive impairment. The methods may also be more generally directed to improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a disease or condition associated with neuronal or synaptic loss according to the disclosed regimens.

Abstract: The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one antioxidant enzyme inhibitor. The pharmaceutical combination of the present invention exhibits synergistic effect when used in the treatment of cancer.

Abstract: Described herein are methods for treating one or more skin conditions by administering, via the sublingual or buccal route, a composition comprising substituted or unsubstituted diindolylmethane. In particular, methods are provided for improving the bioavailability and pharmacokinetic parameters of substituted or unsubstituted diindolylmethane following a sublingual or buccal administration, relative to an oral administration.

Abstract: In one aspect, methods and compositions are provided for treating a subject suffering from or susceptible to prenatal opioid exposure. In a further aspect, methods and compositions are provided for treating a subject suffering from or susceptible traumatic brain injury, intracranial hemorrhage, acquired hydrocephalus, demyelinating diseases including multiple sclerosis, neurological symptoms from systemic lupus erythematosus, and neurodegenerative diseases. In an additional aspect, methods and compositions are provided for treating subject having a COVID-19 infection, exhibiting symptoms of a COVID-19 infection, having suspected exposure to COVID-19, or suspected of suffering from long COVID or post-acute sequelae of COVID-19 (PASC).

Abstract: The present invention relates to a composition for preventing or treating coronavirus infectious diseases, comprising a compound that binds to G4 structures of coronaviruses. Since the compound according to the present invention can bind to G4 structures of coronaviruses to stabilize the G4 structures, reduce the protein expression of coronaviruses, and effectively inhibit cell infection by viruses, the compound is expected to be used in the prevention or treatment of coronavirus infectious diseases.

Abstract: An application of a channel blocker in preparation of drugs for treating and/or preventing liver fibrosis is provided, belonging to the field of biomedical technology. A new use of phenytoin sodium is provided. It is demonstrated that at the cell level, the phenytoin sodium can improve liver fibrosis by regulating autophagy and thus affecting the activation of hepatic stellate cells. In this situation, the efficacy of the phenytoin sodium on liver fibrosis is verified at the animal level by establishing a disease model, and the phenytoin sodium can be used to prepare drugs for treating and/or preventing liver fibrosis.

Abstract: The disclosure provides, inter alia, methods of reducing eye redness and/or increasing eye whiteness using alpha-2-adrenergic receptor agonists.

Abstract: The present invention relates to an oral pharmaceutical composition comprising bendamustine in combination with a modified cyclodextrin, such as, e.g., methyl-?-cyclodextrin or hydroxypropyl-?-cyclodextrin. It has surprisingly been found in the context of the invention that such compositions exhibit a greatly improved oral bioavailability, which renders them particularly advantageous for oral therapeutic application, e.g., in the treatment of cancer.

Abstract: The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof in combination with telmisartan or pharmaceutically acceptable forms thereof, in particular for the prophylaxis and/or treatment of one or more renal diseases and/or hypertension in a non-human mammal/non-human mammal patient, such as a dog or a cat.

Abstract: This invention is directed to neuroprotective compositions and methods of using the same to treat neurodegenerative diseases.

Abstract: Specifically, the invention relates to compositions and methods for treating liver ailments, such as compositions and methods for attenuating or ameliorating the development of alcoholic liver disease (ALD), hepatic steatosis, liver oxidative stress and/or hepatic lipogenesis associated with alcohol consumption in a subject by administering a retinoic acid receptor-beta (RAR?) agonist.

Abstract: The present invention relates to a pharmaceutical composition comprising a ?-lactam compound of formula (I), or a stereoisomer, a solvate or a pharmaceutically acceptable salt or ester thereof, and a lactamase inhibitor or an efflux pump inhibitor, and the use thereof for inhibiting microorganisms, particularly bacteria, especially Gram-negative bacteria, wherein each symbol in formula (I) is as defined in the description.

Abstract: Provided herein are methods for preventing biomineralization in brain tissue or neuronal tissue in vivo or in vitro by inhibiting the deposition of hydroxyapatite therein. Also provided are methods for delaying the progression or onset of Alzheimer's disease in a subject and for preventing the development of Alzheimer's disease in a post-traumatic brain injury subject. Contacting the brain tissue or neuronal tissue with or administering to a subject the drugs Levamisole and/or Foscarnet and/or a bisphosphonate inhibits or decreases levels of alkaline phosphatase and calcium and counteracts alpha-glycerophosphate therein to inhibit the activation of spontaneous biomineralization within a brain tissue to decrease or prevent ectopic biomineralization.

Abstract: Disclosed herein are certain compounds capable of inhibiting bacterial RelA/RSH, and/or minimizing and/or inhibiting formation of bacterial biofilms, and/or compromising and/or reducing integrity of formed biofilms, and/or inhibiting the production of toxins by gram-negative bacteria. Also disclosed herein are methods of inhibiting the formation of and/or compromising and/or reducing integrity of formed biofilms, as well as methods of inhibiting production of toxins by gram-negative bacteria using the compounds disclosed herein.

Abstract: The present description relates to methods of treating neurodegenerative diseases characterized by the accumulation of aberrant forms of the microtubule associated protein Tau (MAPT) using substituted thieno[3,2-b]pyridine compounds, forms, and pharmaceutical compositions thereof.

Abstract: Provided herein are methods of treating Tourette Syndrome in a subject in need thereof by administering to the subject compositions comprising a PDE10 inhibitor.

Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.